{"id":"W2944436740","doi":"10.1158/1538-7445.sabcs18-ot2-07-03","title":"Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Trastuzumab emtansine; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Antibody-drug conjugate; Population; Breast cancer; Cancer; Antibody; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00198188,0.001914813,0.00236743,0.0004366689,0.0004099759,0.001532049,0.001030342,0.001907748,0.00950832],"category_scores_gemma":[0.001432602,0.0007173052,0.002286903,0.0005063672,0.001397897,0.001315479,0.000427224,0.004238696,0.002037205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001086937,"about_ca_system_score_gemma":0.001375634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009801544,"about_ca_topic_score_gemma":0.001952885,"domain_scores_codex":[0.9992169,0.0004182356,0.00004225345,0.0001261183,0.0000668584,0.0001296382],"domain_scores_gemma":[0.9988888,0.0002799276,0.0002181062,0.00008670801,0.00006490997,0.0004615221],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9788398,0.008919281,0.0003824619,0.0001858126,0.0004916083,0.00002643055,0.00002415406,0.0001561393,0.002195716,0.00007795836,0.0008437899,0.007856853],"study_design_scores_gemma":[0.9032816,0.09381187,0.001178117,0.00001786936,0.0004086885,0.0000237441,0.00001672666,0.000304214,0.0003440892,0.0001412429,0.0004614969,0.00001050602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866908,0.002765205,0.0005466806,0.001101795,0.0006826434,0.003243382,0.001778811,0.0001371769,0.003053521],"genre_scores_gemma":[0.9838898,0.001764698,0.0012317,0.001863619,0.0007723533,0.003229111,0.00175733,0.00004009333,0.00545135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00950832,"threshold_uncertainty_score":0.0318085,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06120181701635168,"score_gpt":0.4287969098125477,"score_spread":0.367595092796196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}